Suven Life Sciences Ltd

Suven Life Scie. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Suven Life Sciences Ltd

₹ 212 0.00%
22 May 11:23 a.m.
suven.com BSE: 530239 NSE: SUVEN
About

Suven Life Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialisation of novel therapeutics for the treatment of neurodegenerative disorders.[1]

Key Points

Primary Focus
The company has been working towards developing new molecules/ compounds in the complex CNS (central nervous system) space. [1]
Most of its lead molecules address the niche areas of cognitive impairments such as amnesia, dementia, narcolepsy, Alzheimer's, delirium, etc. [2]
CNS is the 2nd largest therapeutic category in the pharmaceutical industry and is also one of the fastest growing segments. [3]

Website BSE NSE
  • Market Cap ₹ 4,624 Cr.
  • Current Price ₹ 212
  • High / Low ₹ 218 / 83.0
  • Stock P/E
  • Book Value ₹ 5.04
  • Dividend Yield 0.00 %
  • ROCE -84.4 %
  • ROE -84.6 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Stock is trading at 42.2 times its book value
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -12.0% over past five years.
  • Company has a low return on equity of -54.0% over last 3 years.
  • Debtor days have increased from 45.2 to 73.4 days.
  • Working capital days have increased from 399 days to 781 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Healthcare Industry: Miscellaneous

Part of BSE Healthcare BSE SmallCap BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
4 4 4 3 3 4 3 2 2 1 3 2 1
24 25 26 55 34 32 27 49 33 32 55 41 45
Operating Profit -20 -21 -22 -52 -32 -28 -24 -46 -30 -31 -52 -39 -44
OPM % -467% -596% -494% -1,719% -1,208% -737% -768% -1,885% -1,267% -3,024% -2,032% -2,435% -2,981%
0 6 0 2 6 6 13 6 4 4 4 2 1
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 1 2 2 2 2 2 2 2 2 1 1 2 1
Profit before tax -21 -16 -23 -51 -28 -24 -13 -42 -28 -28 -50 -39 -44
Tax % 0% 0% 0% 0% 0% 0% 0% 0% -4% 0% 0% 0% 0%
-21 -16 -23 -51 -28 -24 -13 -42 -27 -28 -50 -39 -44
EPS in Rs -0.95 -0.75 -1.06 -2.34 -1.27 -1.10 -0.58 -1.91 -1.22 -1.29 -2.28 -1.79 -2.01
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2008 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
117 521 499 543 625 286 13 13 12 14 12 7
105 361 398 414 427 300 128 93 134 139 140 172
Operating Profit 13 159 102 129 198 -14 -116 -80 -122 -126 -128 -166
OPM % 11% 31% 20% 24% 32% -5% -917% -593% -1,032% -929% -1,094% -2,489%
3 9 19 21 23 27 14 8 5 14 29 11
Interest 5 5 6 6 5 2 1 1 1 0 0 0
Depreciation 4 12 18 21 21 11 4 4 4 7 6 6
Profit before tax 6 152 98 123 196 0 -106 -77 -122 -118 -106 -161
Tax % -32% 28% 26% 29% 37% 15,038% -11% -7% 0% 0% -1% 0%
8 109 72 87 124 -24 -94 -72 -122 -118 -105 -161
EPS in Rs 0.48 5.70 3.76 4.57 6.48 -1.25 -4.94 -3.78 -5.59 -5.42 -4.82 -7.37
Dividend Payout % 35% 7% 35% 15% 15% -80% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: -35%
5 Years: -12%
3 Years: -17%
TTM: -43%
Compounded Profit Growth
10 Years: %
5 Years: -21%
3 Years: -10%
TTM: -37%
Stock Price CAGR
10 Years: 27%
5 Years: 45%
3 Years: 43%
1 Year: 116%
Return on Equity
10 Years: -13%
5 Years: -62%
3 Years: -54%
Last Year: -85%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2008 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 12 13 13 13 13 13 13 13 15 22 22 22
Reserves 95 547 583 654 755 226 131 95 82 354 248 88
55 109 83 71 34 3 6 5 3 2 1 0
38 105 74 78 118 62 33 16 9 12 14 25
Total Liabilities 199 773 751 816 919 303 182 128 108 389 285 135
110 172 305 306 308 22 25 21 38 37 28 60
CWIP 4 107 7 10 25 0 0 5 4 0 0 0
Investments 2 0 0 301 279 223 0 0 45 46 76 22
83 494 439 199 308 58 157 103 22 305 181 53
Total Assets 199 773 751 816 919 303 182 128 108 389 285 135

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2008 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
4 143 68 109 70 -53 -135 -96 -128 -116 -115 -154
-16 -110 -39 -311 -1 30 146 56 -22 -248 94 155
6 179 -68 -30 -52 5 3 35 146 396 -1 -1
Net Cash Flow -7 212 -39 -232 17 -18 14 -5 -4 32 -22 0

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2008 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 111 28 39 31 36 3 66 48 40 22 40 73
Inventory Days 200 165 183 222 329 0
Days Payable 157 89 78 91 134
Cash Conversion Cycle 154 105 144 162 231 3 66 48 40 22 40 73
Working Capital Days 139 69 73 63 100 23 734 1,139 285 293 123 781
ROCE % 8% 13% 15% 24% -4% -54% -58% -118% -53% -36% -84%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
64.98% 64.98% 69.56% 69.56% 69.56% 69.56% 69.56% 69.56% 70.26% 70.26% 70.26% 70.26%
0.45% 0.48% 0.46% 0.51% 0.48% 0.50% 0.54% 0.46% 0.45% 0.33% 0.34% 0.25%
0.39% 0.12% 0.11% 0.11% 0.08% 0.01% 0.01% 1.05% 1.05% 1.05% 1.05% 0.01%
34.18% 34.41% 29.85% 29.80% 29.88% 29.92% 29.88% 28.91% 28.21% 28.34% 28.35% 29.47%
No. of Shareholders 81,03880,11680,83878,63476,29180,95374,00368,95966,11663,97563,53764,603

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Right Issue

Credit ratings

Concalls